Tools
ToolsTheodosiou, Anastasia A., Bogaert, Debby, Cleary, David W., Fady, Paul Enguerrand, Feehily, Conor, Gilbert, Jack A., Greenhough, Beth, Guardabassi, Luca, Hall, Lindsay J., Harman, Toni, Kuijper, Ed J., Lebeer, Sarah, Lorimer, Jamie, Spector, Tim D. and Jones, Chrissie E. (2026) Microbiome research in practice:priorities for clinical translation and impact. Clinical Microbiology and Infection. ISSN 1198-743X
Full text not available from this repository. (Request a copy)Abstract
Background Rapid advances in microbiome science have sparked clinical and commercial enthusiasm for interventions, yet translation into practice risks outpacing both mechanistic understanding and the infrastructure required for safe adoption. Objectives To outline a coordinated research, clinical, social, and policy agenda for advancing safe, effective, and equitable microbiome-based interventions. Sources We convened an interdisciplinary Royal Society-funded expert workshop (Leeds, UK, October 2024) with international leaders in microbiome science, clinical trials, regulation, and social science. Thematic analysis of workshop discussions and written contributions identified priority domains for translation. Content Three intersecting priorities emerged: scientific credibility, practical viability, and stakeholder engagement. Scientific credibility demands investment in multiomic and strain-level characterization of host-microbiome interactions on a large scale, benchmarking of clinical and microbiological endpoints, and harmonization of trial conduct and reporting. Clinical adoption requires fit-for-purpose regulation, diversified investment to address funding bottlenecks, and coordinated capacity building. Meaningful stakeholder engagement with clinicians, patients, policymakers, and the public is essential to foster confidence, develop clinically relevant research questions, and ensure equitable implementation of any new technology. Implications To realize the clinical impact of microbiome interventions, sustained collaboration across disciplines is essential. This review offers a translational roadmap and actionable priorities to accelerate safe, effective, and equitable microbiome-based interventions—ensuring the field fulfils its clinical potential and delivers real-world impact.
| Item Type: | Article |
|---|---|
| Additional Information: | Publisher Copyright: © 2026 The Authors. |
| Uncontrolled Keywords: | clinical trials,evidence-based practice,microbiome,stakeholder participation,translational,microbiology (medical),infectious diseases ,/dk/atira/pure/subjectarea/asjc/2700/2726 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 01 May 2026 10:33 |
| Last Modified: | 02 May 2026 12:57 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/102872 |
| DOI: | 10.1016/j.cmi.2026.01.021 |
Actions (login required)
 |
View Item |